What is the optimal treatment for an adult with stage IV anal squamous carcinoma metastatic to the liver and regional lymph nodes?

Treatment of Stage IV Anal Cancer with Liver and Lymph Node Metastases

Carboplatin plus paclitaxel is the standard first-line treatment for chemotherapy-naïve metastatic anal squamous cell carcinoma, demonstrating superior overall survival of 20 months compared to 12.3 months with cisplatin/5-FU. 1

First-Line Systemic Therapy

Carboplatin-paclitaxel should be initiated as the preferred regimen based on the InterAACT randomized controlled trial, which established this as standard of care with Level I, Grade B evidence. 1, 2

• The objective response rate was 59% (95% CI 42.1%-74.4%) with carboplatin-paclitaxel versus 57% for cisplatin/5-FU. 1
• The hazard ratio for overall survival favored carboplatin-paclitaxel at 2.00 (95% CI 1.15-3.47, P=0.014). 1, 2
• Serious adverse events occurred in only 36% of patients compared to 62% with cisplatin/5-FU (P=0.016), making it better tolerated. 2

Alternative First-Line Options

If carboplatin-paclitaxel is contraindicated or unsuitable, consider these alternatives:

• FOLFCIS (5-FU, leucovorin, cisplatin) achieved a 48% response rate with median OS of 22.1 months in retrospective data. 2
• Cisplatin plus 5-FU/capecitabine remains an option but carries higher toxicity (Level III, Grade B evidence). 1
• Modified DCF (docetaxel, cisplatin, 5-FU) has Category 2B recommendation with encouraging phase II activity. 2
• FOLFOX (5-FU, leucovorin, oxaliplatin) is documented as safe and effective. 2

Liver-Directed Therapy for Oligometastatic Disease

After achieving disease control with systemic chemotherapy, solitary or limited liver metastases should be evaluated for surgical resection or ablation. 2, 3

Treatment Algorithm for Oligometastatic Disease

• Initiate carboplatin-paclitaxel and reassess after 2-3 cycles with cross-sectional imaging. 2
• If good response with solitary resectable liver lesion, refer for multidisciplinary discussion regarding surgical resection or radiofrequency ablation. 2, 3
• Retrospective data from 106 patients showed that resection or ablation of liver metastases can achieve long-term survival, with anal cancer patients experiencing better outcomes than other squamous cell carcinomas. 2
• Patients treated with multimodal therapy (chemotherapy plus ablative treatment) achieved median OS of 22 months versus 13 months with chemotherapy alone (p=0.002). 3

Important caveat: While not yet incorporated into formal guidelines, liver-directed therapy is reasonable for carefully selected patients with solitary, resectable lesions who demonstrate good chemotherapy response. 2

Role of Radiation Therapy

Definitive pelvic radiotherapy combined with chemotherapy should be considered for the primary anal tumor even in metastatic disease. 2

• National Cancer Database analysis showed patients receiving definitive pelvic radiotherapy plus chemotherapy had longer median OS than chemotherapy alone (21.3 months vs 15.9 months; HR 0.70; P<0.001). 2
• Palliative chemoradiotherapy can provide local control for bulky, symptomatic primary tumors after upfront chemotherapy. 2
• Radiotherapy can also be directed at oligometastatic sites (liver, lung) as part of multimodal approach. 4, 5, 3

Second-Line and Subsequent Therapy

If disease progresses on first-line carboplatin-paclitaxel:

• PD-L1 inhibitors (pembrolizumab, nivolumab) should be considered, preferably in clinical trials (Level III, Grade B evidence). 1
• Pembrolizumab in KEYNOTE-028 showed 17% objective response rate and 42% stable disease in PD-L1-positive tumors, with median OS of 9.3 months. 1
• Nivolumab achieved 24% response rate (19% partial, 5% complete) with median OS of 11.5 months in heavily pre-treated patients. 1
• Microsatellite instability/mismatch repair testing is NOT required for PD-1/PD-L1 inhibitor use in metastatic anal cancer. 1

Alternative second-line chemotherapy options include cisplatin-5-FU, carboplatin, doxorubicin, taxanes, irinotecan ± cetuximab, or combinations (Level III, Grade B evidence). 1

Prognosis

• Overall 5-year relative survival for metastatic anal cancer is approximately 30%. 2
• Median OS with carboplatin-paclitaxel is 20 months. 1, 2
• Patients with solitary, resectable liver metastases treated with multimodal therapy may experience extended survival beyond these benchmarks. 2, 3

Key Clinical Pitfalls

• Do not delay systemic therapy to pursue upfront surgical resection of metastases; chemotherapy should establish disease control first. 2
• Do not dismiss local therapy options for the primary tumor even in metastatic setting, as definitive pelvic treatment improves survival. 2
• Do not overlook oligometastatic disease that may benefit from ablative approaches after good chemotherapy response. 2, 3
• Consider immunotherapy early in treatment planning, particularly for patients with good performance status who may benefit from clinical trial enrollment. 1